Report an error

Spotted something inaccurate in “PCSK9 Inhibitor Evolocumab Cuts Major CV Events 31% in Diabetics Without Known Significant Atherosclerosis”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.